tbuckley/cabot-search huggingface dataset:
Conserved roles of mouse DUX and human DUX4 in activating cleavage-stage genes and MERVL/HERVL retrotransposons
Authors: Peter G Hendrickson, Jessie A Doráis, Edward J Grow, Jennifer L Whiddon, Jong-Won Lim, Candice L Wike, Bradley D Weaver, Christian Pflueger, Benjamin R Emery, Aaron L Wilcox, David A Nix, C Matthew Peterson, Stephen J Tapscott, Douglas T Carrell, Bradley R Cairns
Journal: Nature Genetics (2017)
Reassessment of an Asthma Diagnosis
Authors: Lawrence W. Raymond
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Brexit’s Great Repeal Bill will axe the right to health
Authors: Peter Roderick, Allyson M Pollock
Journal: BMJ (2017)

Essential protections will be lost if government plans go ahead

The fundamental right to health in the UK will be lost if the government proceeds with its plan not to convert the EU Charter of Fundamental Rights1 into UK law, as announced in the white paper on the Great Repeal Bill.2

The value of this charter was shown last year, in both EU3 and UK4 courts, when the tobacco industry unsuccessfully challenged the new rules on plain packaging of cigarettes.5 6 One of the industry’s arguments was that the rules violated its rights. Both the EU Court of Justice and the High Court in London used the right to health in article 35 of the charter as a counter weight to that argument. Mr Justice Green made the strongest judicial statement yet in the UK on this critical point:

> [Tobacco regulations] are health measures. This is an area of legislative activity to which immense importance is …
A Year at the Bedside With Osler
Authors: Jason Liebowitz
Journal: JAMA Internal Medicine (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Unexplained Illness Among Persian Gulf War Veterans in an Air National Guard Unit: Preliminary Report—August 1990-March 1995
Journal: JAMA (1995)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Mechanical Adaptability of the MMP‐Responsive Film Improves the Functionality of Endothelial Cell Monolayer
Authors: Mi Hu, Hao Chang, He Zhang, Jing Wang, Wen‐xi Lei, Bo‐chao Li, Ke‐feng Ren, Jian Ji
Journal: Advanced Healthcare Materials (2017)

Extracellular matrix and cells are inherent in coordinating and adapting to each other during all physiological and pathological processes. Synthetic materials, however, show rarely reciprocal and spatiotemporal responses to cells, and lacking self‐adapting properties as well. Here, a mechanical adaptability based on the matrix metalloproteinase (MMPs) sensitive polyelectrolyte film is reported. Poly‐lysine (PLL) and methacrylated hyaluronic acid (HA‐MA) nanolayers are employed to build the thin film through the layer‐by‐layer assembly, and it is further crosslinked using MMP sensitive peptides, which endows the films with changeable mechanical properties in response to MMPs. It is demonstrated that stiffness of the (PLL/HA‐MA) films increases with the crosslinking, and then decreases in response to a treatment of enzyme. Consequently, the crosslinked (PLL/HA‐MA) films reveal effective growth of endothelial cells (ECs), leading to fast formation of EC monolayer. Importantly, significantly improved endothelial function of the EC monolayer, which is characterized by integrity, biomolecules release, expression of function related gene, and antithrombotic properties, is achieved along with the decrosslinking of the film because of EC‐secreted MMPs. These results suggest that mechanical adaptability of substrate in Young's modulus plays a significant role in endothelial progression, which shows great application potential in tissue engineering, regenerative medicine, and organ‐on‐a‐chip.
Manufacturing of Mesenchymal Stromal Cells for the Treatment of Graft-Versus-Host Disease: A Survey within the European Society of Blood and Marrow Transplantation
Authors: Trento Cristina, Maria Ester Bernardo, Arnon Nagler, Selim Kuci, Martin Bornhäuser, Ulrike Köhl, Dirk Strunk, Giuseppe Gaipa, Martino Introna, Lorenza Lazzari, Jane F. Apperley, Adomas Bukauskas, Katarina Le Blanc, Ann Van Campenhout, Yves Beguin, Jurgen Kuball, Steffi Maria van der Werf, Carmen Ruiz de Elvira, Christian Chabannon, Helene Roelofs, Chiara Bonini, Francesco Dazzi
Journal: Blood (2016)
The Role of MLL1 and MLL2 in MLL Fusion Oncoprotein-Initiated Leukemia
Authors: Patricia Ernst, Konstantinos Anastassiadis, Andrea Kranz, A. Francis Stewart, Kathrin Arndt, Claudia Waskow, Akihiko Yokoyama, Kenneth Jones, Tobias Neff, Yufei Chen
Journal: Blood (2016)
Correlative study of low serum creatinine and hematological toxicities in Japanese patients with ovarian cancer treated by dose dense TC therapy.
Authors: Koji Matsumoto, Takuma Onoe, Akihito Kitao, Maki Tanioka, Shunichi Negoro
Journal: Journal of Clinical Oncology (2012)

5045 Background: Dose dense TC (ddTC) is a novel standard therapy for patients (pts) with advanced ovarian cancer, although hematological toxicities (hemTX), especially anemia, may increase as observed in NOVEL trial (JGOG3016). Low serum creatinine (LCr), especially below 0.7 mg/dl, may lead to overestimation of GFR. GOG announced that pts with LCr should use a minimum value of 0.7mg/dl to estimate GFR. The correlation between LCr and hemTX treated by ddTC is unknown. Methods: GFR was determined using the Cockcroft-Gault formula. Serum creatinine concentrations were measured using enzymatic assays. Minimum value of 0.7 mg/dl was not used during this period of time. The carboplatin clearance was then calculated by Calvert equation. HemTX were defined as, Grade 3 or 4 (by CTC-AE ver.4) neutropenia, anemia, and thrombocytopenia. Using electrical chart, frequency of hemTX and correlation between serum creatinine (less than 0.7 or not) were examined. Results: From Feb. 2010 to Dec. 2011, 61 consecutive pts were treated with ddTC. LCr was observed in 73% of pts. No treatment related death occurred. Among 61 pts, 50 (82%), 31 (51%), and 12 (19.6 %) pts experienced Grade3/4 neutropenia, anemia and thrombocytopenia, respectively. HemTX in pts with LCr and the others were as in the Table. Conclusions: LCr is frequent in Japanese female pts. ddTC in practice setting seems safe, and hemTX of ddTC are similar with those observed in NOVEL trial. The rationale using a minimum value of 0.7 mg/dl should be further studied by larger population, such as pts in NOVEL trial. [Table: see text]
Carotid Artery Stenting Versus Endarterectomy for Stroke Prevention
Authors: Partha Sardar, Saurav Chatterjee, Herbert D. Aronow, Amartya Kundu, Preethi Ramchand, Debabrata Mukherjee, Ramez Nairooz, William A. Gray, Christopher J. White, Michael R. Jaff, Kenneth Rosenfield, Jay Giri
Journal: Journal of the American College of Cardiology (2017)
A first-in-human phase 1 study of anticancer stem cell agent OMP-54F28 (FZD8-Fc), decoy receptor for WNT ligands, in patients with advanced solid tumors.
Authors: Antonio Jimeno, Michael S. Gordon, Rashmi Chugh, Wells A. Messersmith, David S. Mendelson, Jakob Dupont, Robert J. Stagg, Ann Kapoun, Lu Xu, Rainer Karl Brachmann, David C. Smith
Journal: Journal of Clinical Oncology (2014)

2505 Background: The WNT/FZD signaling pathway is implicated in tumor cell de-differentiation and cancer stem cell (CSC) function in numerous cancer types. As a first-in-class recombinant fusion protein, OMP-54F28 binds WNT ligands and blocks WNT signaling through its domain of an extracellular part of human Frizzled 8 receptor (fused to a human IgG1 Fc fragment). In patient-derived xenograft models, OMP-54F28 inhibits growth and CSC frequency, promotes differentiation of tumor cells, and synergizes with chemotherapy in a broad spectrum of malignancies. Methods: A 3+3 design was used; OMP-54F28 was given intravenously every 3 weeks. Objectives were determination of maximum tolerated dose (MTD), safety, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy. Results: 25 patients were treated in 7 dose-escalation cohorts (0.5, 1, 2.5, 5, 10, 15 and 20 mg/kg). No further dose escalation was pursued as animal data and PK modeling indicated 10 mg/kg as the target efficacious dose. Most common related Grade 1 and 2 adverse events (AEs; ≥20% of patients) were dysgeusia, decreased appetite, fatigue, muscle spasms, nausea, and vomiting. No related Grade ≥3 AEs were reported. OMP-54F28 had a half-life of ~4 days at ≥10 mg/kg. Consistent with WNT pathway inhibition in bone, 5 patients had doubling from baseline of bone turnover marker β-C-terminal telopeptide (β-CTX), an event that was reversible (β-CTX return to baseline) upon treatment with a single dose of zoledronic acid. PD modulation of WNT pathway genes was shown in hair follicles at ≥2.5 mg/kg. Two desmoid tumor patients have experienced stable disease (SD) for >6 months. 4 of 4 patients at 20 mg/kg with ≥1 on-study tumor assessment continue on study with SD. Conclusions: OMP-54F28 is well tolerated up to 20 mg/kg, double the target efficacious dose. PD modulation in bone and hair follicles was observed. Several patients experienced prolonged SD. Dose escalation is completed, and 3 Phase 1b studies are ongoing (pancreas cancer with nab-paclitaxel and gemcitabine, ovarian cancer with carboplatin and paclitaxel, and hepatocellular cancer with sorafenib). Detailed efficacy, safety, PK and PD results will be presented. Clinical trial information: NCT01608867.
Calcium Intake and Cardiovascular Disease Risk
Authors: Elizabeth J. Samelson
Journal: Annals of Internal Medicine (2017)

Letters2 May 2017Calcium Intake and Cardiovascular Disease RiskElizabeth J. Samelson, PhDElizabeth J. Samelson, PhDFrom Harvard Medical School, Beth Israel Deaconess Medical Center, and Hebrew SeniorLife, Boston, Massachusetts.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L17-0134 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Chung and colleagues (1) conducted a robust meta-analysis and found no association between calcium intake and cardiovascular risk. As they point out, the strength of the evidence linking calcium supplementation with cardiovascular end points is weak and a plausible biological mechanism has not been identified. However, we disagree that data on the calcification of vascular tissues associated with calcium supplementation for the general population do not exist.We assessed the association between calcium intake and the coronary artery calcification Agatston score evaluated from computed tomographic scans in 1200 women and men in the community-based Framingham Heart Study ...References1. Chung M, Tang AM, Fu Z, Wang DD, Newberry SJ. Calcium intake and cardiovascular disease risk: an updated systematic review and meta-analysis. Ann Intern Med. 2016;165:856-66. [PMID: 27776363]. doi:10.7326/M16-1165 LinkGoogle Scholar2. Samelson EJ, Booth SL, Fox CS, Tucker KL, Wang TJ, Hoffmann U, et al. Calcium intake is not associated with increased coronary artery calcification: the Framingham Study. Am J Clin Nutr. 2012;96:1274-80. [PMID: 23134889] doi:10.3945/ajcn.112.044230 CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From Harvard Medical School, Beth Israel Deaconess Medical Center, and Hebrew SeniorLife, Boston, Massachusetts.Disclosures: Authors have disclosed no conflicts of interest. Forms can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=L17-0134. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoCalcium Intake and Cardiovascular Disease Risk Mei Chung , Alice M. Tang , Zhuxuan Fu , Ding Ding Wang , and Sydne Jennifer Newberry Calcium Intake and Cardiovascular Disease Risk Ian R. Reid , Alison Avenell , Andrew Grey , and Mark J. Bolland Calcium Intake and Cardiovascular Disease Risk Mei Chung , Alice M. Tang , and Sydne Jennifer Newberry Calcium Intake and Cardiovascular Disease Risk Aisawan Petchlorlian Calcium Intake and Cardiovascular Disease Risk Joshua R. Lewis and Richard L. Prince Metrics 2 May 2017Volume 166, Issue 9Page: 684KeywordsCalciumCardiovascular disease riskComputed axial tomographyCoronary artery calcificationDisclosureLongitudinal studiesProspective studiesRenal diseasesStable coronary artery diseaseVitamin D ePublished: 2 May 2017 Issue Published: 2 May 2017 Copyright & PermissionsCopyright © 2017 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Vital Signs: Racial Disparities in Age-Specific Mortality Among Blacks or African Americans — United States, 1999–2015
Authors: Timothy J. Cunningham, Janet B. Croft, Yong Liu, Hua Lu, Paul I. Eke, Wayne H. Giles
Journal: MMWR Morbidity and Mortality Weekly Report (2017)

Although the overall life expectancy at birth has increased for both blacks and whites and the gap between these populations has narrowed, disparities in life expectancy and the leading causes of death for blacks compared with whites in the United States remain substantial. Understanding how factors that influence these disparities vary across the life span might enhance the targeting of appropriate interventions.Trends during 1999-2015 in mortality rates for the leading causes of death were examined by black and white race and age group. Multiple 2014 and 2015 national data sources were analyzed to compare blacks with whites in selected age groups by sociodemographic characteristics, self-reported health behaviors, health-related quality of life indicators, use of health services, and chronic conditions.During 1999-2015, age-adjusted death rates decreased significantly in both populations, with rates declining more sharply among blacks for most leading causes of death. Thus, the disparity gap in all-cause mortality rates narrowed from 33% in 1999 to 16% in 2015. However, during 2015, blacks still had higher death rates than whites for all-cause mortality in all groups aged <65 years. Compared with whites, blacks in age groups <65 years had higher levels of some self-reported risk factors and chronic diseases and mortality from cardiovascular diseases and cancer, diseases that are most common among persons aged ≥65 years.To continue to reduce the gap in health disparities, these findings suggest an ongoing need for universal and targeted interventions that address the leading causes of deaths among blacks (especially cardiovascular disease and cancer and their risk factors) across the life span and create equal opportunities for health.
Multiparametric Evaluation of Treatment Response to Neoadjuvant Chemotherapy in Breast Cancer Using Integrated PET/MR
Authors: Jane Wang, Tiffany Ting-Fang Shih, Ruoh-Fang Yen
Journal: Clinical Nuclear Medicine (2017)

The aim of this study was to investigate whether integrated PET/MR system can predict the treatment response to neoadjuvant chemotherapy (NAC) early in the course of breast cancer treatment.Fourteen women with newly diagnosed invasive breast cancer (median age, 54.5 years) were recruited. Each participant underwent 2 PET/MR studies. Study 1 was pre-NAC; study 2 was early in NAC treatment (after the first or second cycle). PET parameters included SUVmax and total lesion glycolysis (TLG). MRI parameters included choline signal-to-noise ratio (ChoSNR), peak enhancement ratio (PER), and the minimum apparent diffusion coefficient (ADCmin). The pathologic response was categorized as a pathologic complete response or residual cellularity of less than 10% (group 1) and residual cellularity of 10% or greater (group 2). The accuracy of the NAC response prediction was obtained by receiver operating characteristic analysis.Group 1 showed a greater reduction of SUVmax (percentage change, [INCREMENT]% SUVmax, P = 0.013; area under the receiver operating characteristic curve [AUC], 0.898), TLG ([INCREMENT]%TLG, P = 0.018; AUC = 0.878), and PER ([INCREMENT]% PER, P = 0.035; AUC = 0.837) than did group 2. The ChoSNR, ADCmin, [INCREMENT]%ChoSNR, and [INCREMENT]%ADCmin did not differ significantly between the 2 groups. The hybrid markers, [INCREMENT]%SUVmax/[INCREMENT]%ADCmin (AUC = 0.976) and [INCREMENT]%TLG/[INCREMENT]%ADCmin (AUC = 0.905), showed greater accuracy in predicting NAC response than the individual PET/MR parameters.The PET/MR parameters can predict the NAC response early in the course of breast cancer treatment. The hybrid markers more accurately predicted treatment response than the individual PET/MR parameters.
A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants
Authors: Qing Zhu, Jason S. McLellan, Nicole L. Kallewaard, Nancy D. Ulbrandt, Susan Palaszynski, Jing Zhang, Brian Moldt, Anis Khan, Catherine Svabek, Josephine M. McAuliffe, Daniel Wrapp, Nita K. Patel, Kimberly E. Cook, Bettina W. M. Richter, Patricia C. Ryan, Andy Q. Yuan, JoAnn A. Suzich
Journal: Science Translational Medicine (2017)

Prevention of respiratory syncytial virus (RSV) illness in all infants is a major public health priority. However, no vaccine is currently available to protect this vulnerable population. Palivizumab, the only approved agent for RSV prophylaxis, is limited to high-risk infants, and the cost associated with the requirement for dosing throughout the RSV season makes its use impractical for all infants. We describe the development of a monoclonal antibody as potential RSV prophylaxis for all infants with a single intramuscular dose. MEDI8897*, a highly potent human antibody, was optimized from antibody D25, which targets the prefusion conformation of the RSV fusion (F) protein. Crystallographic analysis of Fab in complex with RSV F from subtypes A and B reveals that MEDI8897* binds a highly conserved epitope. MEDI8897* neutralizes a diverse panel of RSV A and B strains with >50-fold higher activity than palivizumab. At similar serum concentrations, prophylactic administration of MEDI8897* was ninefold more potent than palivizumab at reducing pulmonary viral loads by >3 logs in cotton rats infected with either RSV A or B subtypes. MEDI8897 was generated by the introduction of triple amino acid substitutions (YTE) into the Fc domain of MEDI8897*, which led to more than threefold increased half-life in cynomolgus monkeys compared to non-YTE antibody. Considering the pharmacokinetics of palivizumab in infants, which necessitates five monthly doses for protection during an RSV season, the high potency and extended half-life of MEDI8897 support its development as a cost-effective option to protect all infants from RSV disease with once-per-RSV-season dosing in the clinic.
Nontuberculous mycobacterial pulmonary disease: an increasing burden with substantial costs
Authors: D. Rebecca Prevots, Robert Loddenkemper, Giovanni Sotgiu, Giovanni Battista Migliori
Journal: European Respiratory Journal (2017)

Increased awareness of nontuberculous mycobacterial pulmonary disease (NTM PD) has led to efforts to more fully describe the burden, epidemiological and clinical features, and cost of this condition in different populations globally. Approaches encompass various methodologies including surveillance, population-based studies, analysis of large linked datasets, surveys, laboratory-based convenience samples and combinations of these approaches. Surveillance has been defined as the "systematic collection, consolidation, and evaluation of morbidity and mortality reports, and… regular dissemination to all who need to know" [1]. For NTM PD, notifiable condition reporting varies. In Queensland, Australia, notification of NTM infections is required; reporting is electronic and laboratory-based [2]. In several states within the USA, NTM isolates or cases are listed as notifiable conditions [3, 4], although in Oregon, only extrapulmonary isolates are listed as notifiable [3]. Although reporting might not be complete, and the system may have biases related to healthcare-seeking behaviour and physician awareness, these data are essential to elucidating the epidemiology of NTM PD [3]. The cost of nontuberculous mycobacterial pulmonary disease is substantial, with high hospitalisation and drug costs <http://ow.ly/8xcl309VgDG>